Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 5/20 | 0.54 |
| ▸ | RAB9A | P51151 | 5/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.53 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | CCR1 | P32246 | 1/20 | 0.50 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.50 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.49 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6224549 | 0.87 | MAPK1 (0.71) | MAPK1NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL6052256 | 0.87 | MAPK1 (0.61) | MAPK1NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL6052522 | 0.86 | MAPK1 (0.53) | MAPK1NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL27692438 | 0.85 | HSD11B1 (0.62) | MAPK1NPC1RAB9AMAPTSLC9A1 | |
| SCHEMBL27405 | 0.85 | MAPK1 (0.78) | MAPK1NPC1RAB9AMAPTSLC9A1 | |
| SCHEMBL1420155 | 0.84 | KMT2A (0.61) | MAPK1NPC1RAB9AALDH1A1NOTUM | |
| SCHEMBL6052319 | 0.84 | MAPK1 (0.58) | MAPK1NPC1RAB9AMAPTSLC9A1 | |
| SCHEMBL2397695 | 0.84 | MAPK1 (0.58) | MAPK1NPC1RAB9AMAPTSLC9A1 | |
| SCHEMBL13505849 | 0.84 | MAPK1 (0.58) | MAPK1NPC1RAB9AMAPTALDH1A1 | |
| SCHEMBL15167464 | 0.83 | MAPK1 (0.54) | MAPK1NPC1RAB9AMAPTSLC9A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2024-04-11 | — | — | US | disclosed |
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2023-08-24 | — | — | US | disclosed |
| US-20210070707-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-20200190030-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2020-06-18 | — | — | US | disclosed |
| US-10344026-B2 | Compositions and methods of targeting mutant K-ras | NANTBIO, INC. (US) | 2019-07-09 | — | — | US | disclosed |
| US-20180258043-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2018-09-13 | — | — | US | disclosed |
| US-20180201610-A1 | COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS | NANTBIO, INC. | 2018-07-19 | — | — | US | disclosed |
| US-20180148447-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | IGNYTA, INC. (US) | 2018-05-31 | — | — | US | disclosed |
| EP-3309160-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | Ignyta, Inc. (US) | 2018-04-18 | — | — | EP | disclosed |
| US-20060063779-A1 | Pyridyl inhibitors of hedgehog signalling | CURIS ROYALTY LLC | 2006-03-23 | — | — | US | disclosed |
| US-7015218-B1 | Amide compounds and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2006-03-21 | — | — | US | disclosed |
| WO-2006028958-A2 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | GENENTECH, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| CN-1230421-C | Amide compound and pharmaceutical use thereof | MITSUBISHI CHEM CORP (JP) | 2005-12-07 | — | — | CN | disclosed |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | ICAGEN, INC. (US) | 2005-03-03 | — | — | US | disclosed |
| EP-1176140-B1 | AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2004-12-29 | — | — | EP | disclosed |
| WO-2004084842-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
| US-20040198780-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-10-07 | — | — | US | disclosed |
| CN-1346348-A | Amide compound and pharmaceutical use thereof | YOSHITOMI PHARMACEUTICAL (JP) | 2002-04-24 | — | — | CN | disclosed |
| EP-1176140-A1 | AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2002-01-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190030-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | MAPK1 128/4885NPC1 2880/4885RAB9A 761/4885 |
| US-20230265054-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | MAPK1 128/4885NPC1 2880/4885RAB9A 761/4885 |
| US-20240116872-A1 | PYRIDYL INHIBITORS FOR HEDGEHOG SIGNALLING | SHH, GLI1, SMO | MAPK1 118/4885NPC1 2910/4885RAB9A 768/4885 |
| US-20180148447-A1 | PYRAZOLO[1,5-A]PYRIDINE DERIVATIVES AND METHODS OF THEIR USE | AXL, FLT3, ERBB2 | MAPK1 121/4885NPC1 4573/4885RAB9A 1736/4885 |
| US-20050049237-A1 | Pyrazole-amides and -sulfonamides | SCN3A, TRPV3, HCN3 | MAPK1 1878/4885NPC1 3322/4885RAB9A 3176/4885 |
| US-10344026-B2 | Compositions and methods of targeting mutant K-ras | KRAS, NRAS, HRAS | MAPK1 633/4885NPC1 2166/4885RAB9A 57/4885 |
| US-20210070707-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | MAPK1 128/4885NPC1 2880/4885RAB9A 761/4885 |
| US-20040198780-A1 | Inhibitors of cathepsin S | CTSS, CTSK, CTSE | MAPK1 4290/4885NPC1 333/4885RAB9A 3129/4885 |
| US-20180201610-A1 | COMPOSITIONS AND METHODS OF TARGETING MUTANT K-RAS | KRAS, NRAS, HRAS | MAPK1 633/4885NPC1 2166/4885RAB9A 57/4885 |
| US-20180258043-A1 | PYRIDYL INHIBITORS OF HEDGEHOG SIGNALLING | SHH, GLI1, SMO | MAPK1 128/4885NPC1 2880/4885RAB9A 761/4885 |
| US-20060063779-A1 | Pyridyl inhibitors of hedgehog signalling | SHH, GLI1, SMO | MAPK1 128/4885NPC1 2880/4885RAB9A 761/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.